Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib
| Autor: | Mauricio Alves Ribeiro, Luiz Arnaldo Szutan, Caroline Petersen da Costa Ferreira |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
Sorafenib medicine.medical_specialty Carcinoma Hepatocellular Cirrhosis Multivariate analysis Palliative care Hepatitis C virus Antineoplastic Agents carcinoma hepatocelular neoplasias hepáticas medicine.disease_cause Gastroenterology Neoplasias hepáticas 03 medical and health sciences 0302 clinical medicine inibidores de proteínas quinases Liver neoplasms Internal medicine medicine Humans Neoplasm Staging lcsh:R5-920 business.industry Liver Neoplasms Palliative Care sorafenibe General Medicine hepatocellular carcinoma Middle Aged medicine.disease digestive system diseases protein kinase inhibitors Treatment Outcome 030220 oncology & carcinogenesis Hepatocellular carcinoma Etiology Portal hypertension Female 030211 gastroenterology & hepatology sorafenib Sorafenibe Inibidores de proteínas quinases Epidemiologic Methods business lcsh:Medicine (General) Carcinoma hepatocelular medicine.drug |
| Zdroj: | Revista da Associação Médica Brasileira v.66 n.3 2020 Revista da Associação Médica Brasileira Associação Médica Brasileira (AMB) instacron:AMB Revista da Associação Médica Brasileira, Vol 66, Iss 3, Pp 275-283 Revista da Associação Médica Brasileira, Volume: 66, Issue: 3, Pages: 275-283, Published: 03 JUN 2020 |
| Popis: | SUMMARY Malignant liver tumors are the fourth leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) accounts for 75-85% of these. Most patients are diagnosed at incurable stages. Palliative care is the appropriate treatment course in these circumstances (chemoembolization and sorafenib). There are few national studies on sorafenib. The objective is to evaluate survival predictors of HCC patients treated with sorafenib and evaluate the compliance of its indication in relation to BCLC recommendations. METHODS A total of 88 patients with an indication of sorafenib from 2010 to 2017 at the ISCMSP were retrospectively analyzed. Univariate and multivariate analyzes were performed in the search for predictors of survival. RESULTS The mean age was 61.2 years, 70.5% were men, most were classified as Child-Pugh A (69.3%), and BCLC C (94.3%). Cirrhosis was present in 84.6% and portal hypertension in 55.7%. Hepatitis C virus was the most common etiology (40.9%). Sixty-nine (78.4%) patients received the medication, with the average duration of treatment being 9.7 months. The mean overall survival was 16.8 months. Significant differences were observed in the multivariate analysis: ECOG PS (p = 0.024): Child-Pugh (p = 0.013), time of medication use (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|